Core Viewpoint - The company, 医思健康 (02138), anticipates a decline in financial performance for the six months ending September 30, 2025, compared to the same period in 2024, with significant reductions in revenue, EBITDA, and net profit [1] Financial Performance Summary - Revenue is expected to decrease by no more than 10% from approximately HKD 2.063 billion for the corresponding period ending September 30, 2024 [1] - EBITDA is projected to decline by no more than 30% from approximately HKD 248 million for the same period [1] - Net profit is anticipated to drop by no more than 90% from approximately HKD 40.3 million for the corresponding period [1] Reasons for Decline - The board attributes the decline in net profit and EBITDA to several factors: - Weak local consumer sentiment, including a trend of Hong Kong residents consuming medical and healthcare services in mainland China, along with increased outbound travel, which has weakened local demand for discretionary medical and aesthetic services [1] - The sale of several medical assets in the latter half of the previous fiscal year, which are no longer included in the financial statements, resulting in no revenue contribution during the reporting period [1] - An unfavorable service mix, with a decrease in the proportion of high-margin discretionary services [1] - A reduction in operational leverage due to declining revenue [1] Financial Position - The board believes that the overall asset and liability situation of the company remains robust, with expected cash, time deposits, and liquid financial assets totaling approximately HKD 1.1 billion at the end of the reporting period [1]
医思健康发盈警，预期中期纯利减少不多于90%